Collplant, an Israeli regenerative medicine company focused on the 3D bioprinting of tissues and organs has entered into a license, development and commercialization agreement for 3D bioprinted lung transplants.

The agreement combines CollPlant’s proprietary recombinant human collagen (rhCollagen) and BioInk technology with the regenerative medicine and organ manufacturing capabilities of United Therapeutics.

CollPlant technology uses genetically modified tobacco plants to produce collagen.The tobacco is cultivated, for about 8 weeks. Then the tobacco is processed  to make an extract that is purified to produce rhCollagen. This product is ideal to produce “BioInk” to print in 3D, artificial tendons and transparent ophthalmological products.

Martine Rothblatt, Ph.D., chairman and chief executive officer of United Therapeutics, said, “We are excited to work with CollPlant’s extraordinary Israeli technology to transform the tobacco plant that is so associated with lung disease into a collagen-expressing plant that will be essential to the production of an unlimited number of transplantable lungs.”

As of now the license is restricted to 3D lungs.